Hymecromone

Hymecromone

SCHEMBL31014

Cc1cc(=O)oc2cc(O)ccc12.[NaH]

nearest known ligand 0.96

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B3 P37058 8/20 0.96
ALDH1A1 P00352 7/20 0.96
KDM4E B2RXH2 6/20 0.96
CA12 O43570 6/20 0.96
CA9 Q16790 6/20 0.96
HPGD P15428 4/20 0.96
HSD17B10 Q99714 4/20 0.96
GAA P10253 4/20 0.96
GLA P06280 3/20 0.96
AKR1B1 P15121 3/20 0.96
MAOB P27338 3/20 0.96
CASP1 P29466 2/20 0.96
CASP7 P55210 2/20 0.96
MCL1 Q07820 2/20 0.96
LMNA P02545 1/20 0.96
CYP1A2 P05177 1/20 0.96
CYP2C9 P11712 1/20 0.96
UGT1A1 P22309 1/20 0.96
KDR P35968 1/20 0.96
DYRK1A Q13627 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hymecromone SCHEMBL29364837 0.98 HSD17B3 (1.00) HSD17B3ALDH1A1KDM4ECA12CA9
Hymecromone SCHEMBL24150 0.98 HSD17B3 (1.00) HSD17B3ALDH1A1KDM4ECA12CA9
Hymecromone SCHEMBL2357040 0.98 HSD17B3 (1.00) HSD17B3ALDH1A1KDM4ECA12CA9
Hymecromone SCHEMBL29624431 0.98 HSD17B3 (1.00) HSD17B3ALDH1A1KDM4ECA12CA9
Hymecromone SCHEMBL27924142 0.96 HSD17B3 (0.96) HSD17B3ALDH1A1KDM4ECA12CA9
Hymecromone SCHEMBL27728511 0.95 HSD17B3 (0.93) HSD17B3ALDH1A1KDM4ECA12CA9
Hymecromone SCHEMBL2256610 0.93 ALDH1A1 (0.90) HSD17B3ALDH1A1KDM4ECA12CA9
Hymecromone SCHEMBL28882003 0.92 KDM4E (0.87) HSD17B3ALDH1A1KDM4ECA12CA9
Hymecromone SCHEMBL3272842 0.92 HSD17B3 (0.87) HSD17B3ALDH1A1KDM4ECA12CA9
Hymecromone SCHEMBL7594956 0.92 KDM4E (0.87) HSD17B3ALDH1A1KDM4ECA12CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3689352-B1 EVALUATION OF THE SEVERITY OF PATIENTS WITH FLAVIVIRUS INFECTION BY BLOOD HYALURONAN LEVELS AND THERAPEUTIC AGENTS TO BLOCK THE HYALURONAN UNIV KAOHSIUNG MEDICAL (TW) 2023-11-15 EP claimed
US-20210205450-A1 METHOD FOR TREATING SUBJECT SUFFERING FROM FLAVIVIRUS INFECTION KAOHSIUNG MEDICAL UNIVERSITY (TW) 2021-07-08 US claimed
CN-111521594-A Novel nano-composite, preparation method thereof and application thereof in sewage detection 重庆工程职业技术学院 2020-08-11 CN claimed
EP-3689352-A1 EVALUATION OF THE SEVERITY OF PATIENTS WITH FLAVIVIRUS INFECTION BY BLOOD HYALURONAN LEVELS AND THERAPEUTIC AGENTS TO BLOCK THE HYALURONAN Kaohsiung Medical University (TW) 2020-08-05 EP claimed
US-20190107538-A1 EVALUATION OF THE SEVERITY OF PATIENTS WITH FLAVIVIRUS INFECTION BY BLOOD HYALURONAN LEVELS AND THERAPEUTIC AGENTS TO BLOCK THE HYALURONAN KAOHSIUNG MEDICAL UNIVERSITY (TW) 2019-04-11 US claimed
EP-3466426-A1 EVALUATION OF THE SEVERITY OF PATIENTS WITH FLAVIVIRUS INFECTION BY BLOOD HYALURONAN LEVELS AND THERAPEUTIC AGENTS TO BLOCK THE HYALURONAN Kaohsiung Medical University (TW) 2019-04-10 EP claimed
JP-9118597-A None JP disclosed
CN-122055148-A Conjugates, compositions and methods for treating influenza 珀杜研究基金会 2026-05-15 CN disclosed
EP-4389772-A1 TARGETED DELIVERY OF THERAPEUTIC ENZYMES Joint-Stock Company "Generium" (RU) 2024-06-26 EP disclosed
CN-112534260-B Automated liquid phase immunoreaction analysis device and method thereof 韩国帕克特生物科技有限公司 2024-06-21 CN disclosed
CN-118019768-A Targeted delivery of therapeutic enzymes 吉尼瑞姆股份公司 2024-05-10 CN disclosed
EP-3689352-B1 EVALUATION OF THE SEVERITY OF PATIENTS WITH FLAVIVIRUS INFECTION BY BLOOD HYALURONAN LEVELS AND THERAPEUTIC AGENTS TO BLOCK THE HYALURONAN UNIV KAOHSIUNG MEDICAL (TW) 2023-11-15 EP disclosed
US-20230305031-A1 AUTOMATED LIQUID-PHASE IMMUNOASSAY APPARATUS BODITECH MED INC. (KR) 2023-09-28 US disclosed
WO-2011084703-A2 ENZYME ASSAYS ON A DROPLET ACTUATOR ADVANCED LIQUID LOGIC, INC. (US) 2011-07-14 WO disclosed
EP-2325302-A1 Diagnosis and treatment of multiple sulfatase deficiency and others using a formylglycine generating enzyme (FGE) Shire Human Genetic Therapies, Inc. (US) 2011-05-25 EP disclosed
EP-2325301-A1 Diagnosis and treatment of multiple sulfatase deficiency and others using a formylglycine generating enzyme (FGE) Shire Human Genetic Therapies, Inc. (US) 2011-05-25 EP disclosed
US-20110118132-A1 Enzymatic Assays Using Umbelliferone Substrates with Cyclodextrins in Droplets of Oil ADVANCED LIQUID LOGIC, INC. (US) 2011-05-19 US disclosed
CN-1073156-C Novel deaminoneuraminidase and process for producing same SEIKAGUKU KOGYO CO LTD (JP) 2001-10-17 CN disclosed
CN-1156480-A Novel deaminoneuraminidase and process for producing same SEIKAGAKU KOGYO CO LTD (JP) 1997-08-06 CN disclosed
JP-H09118597-A CRYSTALLIZING METHOD OF MACROMOLECULE BEHRINGWERKE AG 1997-05-06 JP disclosed